Chemotherapy Treatment Taxol Ineffective In Treating HER-2 Negative Breast Cancer, NEJM Study Says
The chemotherapy treatment paclitaxel, sold by Bristol-Myers Squibb under the brand name Taxol, is ineffective at treating HER-2 negative breast cancer, the most common form of the disease, according to a study published Thursday in the New England Journal of Medicine, the AP/Google.com reports. [click link for full article]
More: continued here